INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
Werte in diesem Artikel
NEW YORK, March 25, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
The investigation concerns whether Sarepta and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On March 18, 2025, Sarepta issued a press release disclosing the death of "a young man with Duchenne muscular dystrophy . . . following treatment with ELEVIDYS", Sarepta's Duchenne muscular dystrophy drug, "having suffered acute liver failure."
On this news, Sarepta's stock price fell $27.81 per share, or 27.44%, to close at $73.54 per share on March 18, 2025.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Danielle Peyton
Pomerantz LLP
dpeyton@pomlaw.com
646-581-9980 ext. 7980
View original content to download multimedia:https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-sarepta-therapeutics-inc---srpt-302410142.html
SOURCE Pomerantz LLP
Übrigens: Sarepta Therapeutics und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.
Ausgewählte Hebelprodukte auf Sarepta Therapeutics
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Sarepta Therapeutics
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Nachrichten zu Sarepta Therapeutics Inc.
Analysen zu Sarepta Therapeutics Inc.
Datum | Rating | Analyst | |
---|---|---|---|
21.08.2019 | Sarepta Therapeutics Buy | Needham & Company, LLC | |
01.10.2018 | Sarepta Therapeutics Overweight | Cantor Fitzgerald | |
21.06.2018 | Sarepta Therapeutics Outperform | Robert W. Baird & Co. Incorporated | |
20.06.2018 | Sarepta Therapeutics Buy | Needham & Company, LLC | |
19.06.2018 | Sarepta Therapeutics Buy | H.C. Wainwright & Co. |
Datum | Rating | Analyst | |
---|---|---|---|
21.08.2019 | Sarepta Therapeutics Buy | Needham & Company, LLC | |
01.10.2018 | Sarepta Therapeutics Overweight | Cantor Fitzgerald | |
21.06.2018 | Sarepta Therapeutics Outperform | Robert W. Baird & Co. Incorporated | |
20.06.2018 | Sarepta Therapeutics Buy | Needham & Company, LLC | |
19.06.2018 | Sarepta Therapeutics Buy | H.C. Wainwright & Co. |
Datum | Rating | Analyst | |
---|---|---|---|
26.04.2016 | Sarepta Therapeutics Sector Perform | RBC Capital Markets | |
22.04.2016 | Sarepta Therapeutics Sector Perform | RBC Capital Markets | |
20.05.2015 | Sarepta Therapeutics Sector Perform | RBC Capital Markets | |
23.01.2015 | Sarepta Therapeutics Sector Perform | RBC Capital Markets | |
28.10.2014 | Sarepta Therapeutics Neutral | Robert W. Baird & Co. Incorporated |
Datum | Rating | Analyst | |
---|---|---|---|
26.04.2016 | Sarepta Therapeutics Reduce | SunTrust Robinson Humphrey, Inc. |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Sarepta Therapeutics Inc. nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen